Wells Fargo analyst Jim Birchenough raised his price target for Autolus Therapeutics to $50 from $38 after the company filed its annual report on Form 20-F for the fiscal year ended September 2018. The analyst reiterates an Outperform rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.